Neuronasal develops drugs, delivered intranasally, for acute brain injuries. Our first products are for concussion. Neuronasal was founded to create value for patients and investors by licensing and developing drugs to treat acute brain injuries and disease. We plan to develop each of our drugs to p…
Neuronasal develops drugs, delivered intranasally, for acute brain injuries. Our first products are for concussion. Neuronasal was founded to create value for patients and investors by licensing and developing drugs to treat acute brain injuries and disease. We plan to develop each of our drugs to proof of concept and then enter into strategic partnerships or trade sales. Neuronasal’s first two products are repurposed off patent drugs, deferoxamine and N acetyl cysteine, that we will deliver with existing intranasal delivery devices in clinical trials for concussion and intracerebral hemorrhage.
Team (1)
Sectors Neuronasal serves:
Life Sciences
Join Axial's Private M&A Platform
Neuronasal connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
